PUT - SPRINTER OPEN END - NOVO-NORDISK B | Real-time Boerse Frankfurt Warrants 04:34:29 2024-05-30 EDT | ||
| 2.94 EUR | -4.23% |
|
| Current month | -2.54% | ||
| 1 month | -9.17% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-30 | 2.94 | -4.23% |
| 24-05-29 | 3.07 | +0.99% |
| 24-05-28 | 3.04 | +5.19% |
| 24-05-27 | 2.89 | +6.25% |
| 24-05-24 | 2.72 | +1.87% |
Real-time Boerse Frankfurt Warrants
Last update May 30, 2024 at 04:34 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1XAU |
| ISIN | DE000VD1XAU7 |
| Date issued | 2024-03-08 |
| Strike | 1,142 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.28 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.15 € |
|---|---|
| Lowest since issue | 2.64 € |
| Spread | 0.01 € |
| Spread % | 0.34% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
911.5
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.25%
- Stock Market
- Certificates
- Certificat
